684 results on '"Schiffrin EL"'
Search Results
2. No Longer a Sine Qua Non for Guideline Authors?
3. Who is an expert? Reply
4. Reply
5. Plasma matrix metalloproteinase (MMP)-9 and tissue inhibitor of MMPS (TIMP)-1 in hypertension: a meta-analysis
6. BIOMARKERS UPDATE: CURRENT AND FUTURE ROLES
7. AT2 Receptors in the Cardiovascualar System
8. Mycophenolat mofetil reduziert Blutdruck und Proteinurie in salzbelasteten SHRSP
9. Endothelial function and dysfunction. Part I: Methodological issues for assessment in the different vascular beds: a statement by the Working Group on Endothelin and Endothelial Factors of the European Society of Hypertension
10. Endothelial function and dysfunction. Part I: Methodological issues for assessment in the different vascular beds: A statement by the Working Group on Endothelin and Endothelial Factors of the European Society of Hypertension RID E-9967-2010
11. NEW TREATMENT FOR HYPERTENSION (EPLERENONE, OMAPATRILAT)
12. The 2001 Canadian recommendations for the management of hypertension: Part two--Therapy
13. ANGIOTENSIN II-INDUCED TRANSGLUTAMINASE 2 REGULATES P-38 MAP-KINASE LONG TERM EXPRESSION IN SHR VASCULAR SMOOTH MUSCLE CELLS: 2C.02
14. Professor Alberto C. Taquini
15. L'endothéline est-elle impliquée dans l'hypertension ?
16. Correspondence
17. Vascular remodeling in hypertension: mechanisms and treatment.
18. Plasma levels of matrix metalloproteinases and their inhibitors in hypertension: a systematic review and meta-analysis.
19. Deleterious combined effects of salt-loading and endothelial cell restricted endothelin-1 overexpression on blood pressure and vascular function in mice.
20. T lymphocytes: a role in hypertension?
21. Aldosterone induces arterial stiffness in absence of oxidative stress and endothelial dysfunction.
22. Chronic kidney disease: effects on the cardiovascular system.
23. Inflammation in hypertension.
24. Mitogen-activated protein kinase activation by hydrogen peroxide is mediated through tyrosine kinase-dependent, protein kinase C-independent pathways in vascular smooth muscle cells: upregulation in spontaneously hypertensive rats.
25. Dual angiotensin-converting enzyme/neutral endopeptidase inhibition on cardiac and renal fibrosis and inflammation in DOCA-salt hypertensive rats.
26. Endothelial function and dysfunction. Part I: Methodological issues for assessment in the different vascular beds: a statement by the Working Group on Endothelin and Endothelial Factors of the European Society of Hypertension.
27. Brain mineralocorticoid receptors: orchestrators of hypertension and end-organ disease.
28. ACE inhibition or angiotensin receptor blockade: which should we use in diabetic patients?
29. Angiotensin II stimulates DNA and protein synthesis in vascular smooth muscle cells from human arteries: role of extracellular signal-regulated kinases.
30. Relationship between small-artery structure and systolic, diastolic and pulse pressure in essential hypertension.
31. Endothelin and endothelin antagonists in hypertension.
32. Mechanical properties of mesenteric resistance arteries from Dahl salt-resistant and salt-sensitive rats: role of endothelin-1.
33. Effects of enalapril and amlodipine on small-artery structure and composition, and on endothelial dysfunction in spontaneously hypertensive rats.
34. How to assess vascular remodelling in small and medium-sized muscular arteries in humans.
35. Structure and function of resistance arteries of hypertensive patients treated with a beta-blocker or a calcium channel antagonist.
36. Differential effects of vasopressin and endothelin-1 on vascular contractile and calcium responses in pressurized small arteries from spontaneously hypertensive rats.
37. Media-to-lumen ratio as predictor of renal abnormalities in hypertension: new findings, new questions.
38. Low birth weight and insulin resistance: can capillary recruitment predict hypertension development?
39. The Pituitary and Hypertension
40. The 2005 Canadian Hypertension Education Program recommendations for the management of hypertension: Part I - Blood pressure measurement, diagnosis and assessment of risk
41. The 2005 Canadian Hypertension Education Program recommendations for the management of hypertension: Part II - Therapy
42. Plasma Concentration of Atrial Natriuretic Factor in a Patient with Paroxysmal Atrial Tachycardia
43. Effect of treatment on cardiac small resistance arteries in hypertension and diabetes: trick or treat.
44. Blood pressure lowering in PROGRESS (Perindopril Protection Against Recurrent Stroke Study) and white matter hyperintensities: should this progress matter to patients?
45. Calcium, magnesium, and oxidative stress in hyperaldosteronism.
46. CARDIAC MICROVASCULAR CHANGES IN DOCA-SALT HYPERTENSIVE RATS.
47. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis.
48. Tissue Proteomics in Vascular Disease
49. Advances in understanding of the role of immune cell phenotypes in hypertension and associated vascular disease.
50. New Kids on the Hypertension Block: Novel Agents With New Mechanisms of Action.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.